Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor: Structure Optimization and Pharmacokinetics

Rahmawati Ridwan, Paul Kiptoo, Naoki Kobayashi, Scott Weir, Michael Hughes, Todd Williams, Rondang Soegianto, and Teruna J. Siahaan

Department of Pharmaceutical Chemistry (R.R., P.K., T.J.S.) and Mass Spectrometry Laboratory (T.W.), University of Kansas, Lawrence, Kansas; Astellas Pharma Inc., Yaizu, Shizuoka, Japan (N.K.); Cancer Center, University of Kansas, Kansas City, Kansas (S.W., M.H.); and Faculty of Medicine, University of Indonesia, Jakarta, Indonesia (R.S.)

Received August 31, 2009; accepted December 14, 2009

ABSTRACT

The objective of this study was to optimize the in vivo activity of proteolipid protein (PLP)-bifunctional peptide inhibitor (BPI) molecule to suppress experimental autoimmune encephalomyelitis (EAE) in SJL/J mice and evaluate pharmacokinetic profiles of PLP-BPI. PLP-BPI is constructed via conjugation of myelin PLP139-151 with CD11a237-246-derived peptide (LABL) via a spacer. The hypothesis is that PLP-BPI binds simultaneously to major histocompatibility complex-II and intercellular adhesion molecule-1 on the antigen-presenting cell (APC) and inhibits the formation of the immunological synapse during T-cell and APC interactions. In this study, the structure of BPI was modified by varying the spacer and was evaluated in the EAE model. Intravenous injections of BPI derivatives inhibited the onset, severity, and incidence of EAE more effectively and induced a lower incidence of anaphylaxis than that produced by unmodified PLP-BPI. As anticipated, production of interleukin-17, a proinflammatory cytokine commonly found in elevated levels among multiple sclerosis (MS) patients, was significantly lower in Ac-PLP-BPI-PEG6- or Ac-PLP-BPI-NH2-2-treated mice than in phosphate-buffered saline-treated mice. These results suggest that BPI-type molecules can be modified to achieve more efficient and better tolerated BPI-based derivatives for the treatment of MS.

Multiple sclerosis (MS), a demyelinating disease affecting the central nervous system, is characterized by inflammatory demyelinating foci in the brain white matter with variable axonal damage (Huizinga et al., 2008; Rueda et al., 2008). Although its etiology is still scarcely understood, the composition of plaques, immunogenetic background, responses to immunomodulation, and data from animal models suggest that MS is mediated by myelin-specific CD4+ T cells (Lu, 2006; Sonobe et al., 2007; Elyaman et al., 2008; Sabatino et al., 2008). It is believed that in autoimmune diseases (e.g., MS, type 1 diabetes, and rheumatoid arthritis), the activation of autoreactive T cells is caused by the recognition of the self-antigen (i.e., fragments of self-protein) before the attack of self-organs. In the case of MS, the activation of a subpopulation of T cells may cause damage to the central nervous system by attacking the myelin sheath proteins on the nerve fibers.

Currently, MS patients are being treated with anti-inflammatory agents (e.g., corticosteroids, interferon, mitoxantrone), Copaxone, and Tysabri. Copaxone (Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel) (Glatiramer) is a synthetic peptide polymer designed as a decoy for the myelin basic protein; it has been suggested to alter the immune response from T helper (Th) type 1 to Th type 2 (Johnson, 1996). Tysabri (natalizumab; Biogen Idec, Cambridge, MA) is a recombinant human monoclonal antibody that inhibits leukocyte adhesion to vascular endothelium by binding to very late antigen-4 (VLA-4), a subunit of the integrin leucocyte function-associated antigen-1, and prevents lymphocytes and monocytes from moving from the circulation into the brain and spinal cord. The side effects observed with Tysabri are serious and may include progressive multifocal leukoencephalopathy (PML), a rare virus that infects the brain and spinal cord, and progressive multifocal leukoencephalitis (PML), a serious and often fatal disease caused by a virus that infects the brain and spinal cord. Other therapies currently under investigation include interferon, glatiramer acetate, and mitoxantrone.

This work was supported by the National Institutes of Health [Grant R01-AT06280] and the Multiple Sclerosis Society. R.R., P.K., and T.J.S. contributed equally to this research. Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. doi:10.1124/jpet.109.161109.

ABBREVIATIONS: MS, multiple sclerosis; EAE, experimental autoimmune encephalomyelitis; PLP, proteolipid protein; BPI, bifunctional peptide inhibitor; LFA-1, lymphocyte function-associated antigen-1; ICAM-1, intercellular adhesion molecule molecule-1; MHC, major histocompatibility complex; APC, antigen-presenting cell; TCR, T cell receptor; IL-17, interleukin-17; AUC, area under curve; Th, T helper; SMAC, supramolecular activation cluster; PBS, phosphate-buffered saline; CFA, complete Freund’s adjuvant; LC-MS/MS, liquid chromatography tandem mass spectrometry; QC, quality control; IS, internal standard; APL, altered peptide ligand; MOG, myelin oligodendrocyte protein; TGF, transforming growth factor; T-reg, regulatory T cell.
T lymphocyte adhesion by binding to the α4β1 and α5β1 integrins on the surface of leucocytes except neutrophils (Langer-Gould et al., 2005; Kappos et al., 2007). Because of fatalities in two patients who were infected with JC virus in the brain, Tysabri was once withdrawn from the market but was later reinstated for clinical use with some cautions. It was speculated that blocking the leucocyte adhesion signal (signal 2) may have compromised the general immune response, including the subpopulation that can fight viral infections. Thus, there is an urgent need to develop therapies that can selectively suppress a subpopulation of T cells that causes the progression of the autoimmune diseases without compromising the general immune response.

The initiating event in the activation of autoreactive CD4+ T cells is triggered by the interaction between T cells and antigen-presenting cells (APCs) through receptor/ligand-like molecular combinations widely referred to as signal 1 and signal 2 (Grakoui et al., 1999; Bromley et al., 2001). Signal 1 includes the interaction between T-cell receptors (TCRs) on the surface of T cells and antigen-loaded major histocompatibility complex (MHC) on the surface of APCs (Frauwirth and Thompson, 2002). Signal 2, also referred to as the costimulatory signal, can be caused by interaction of a variety of molecular pairs such as lymphocyte function-associated antigen-1 (LFA-1)/intercellular adhesion molecule-1 (ICAM-1), CD28/B7, CTLA-4/B7, inducible costimulatory/inducible co-stimulator ligands, and PD-1/PD-1 ligands (Grakoui et al., 1999; Schaub et al., 1999; Bromley and Dustin, 2002). Initially, the TCR/MHC-peptide complexes (signal 1) are formed in the peripheral region, and the ICAM-1/LFA-1 complexes (signal 2) are formed in the central region. Then, the ICAM-1/LFA-1 clusters translocate to the outer region, and the TCR/MHC-peptide complexes congregate at the center to form the inner region. In the final state, TCR/MHC-peptide complexes congregate at the center to form the central supramolecular activation clusters (SMACs) and the LFA-1/ICAM-1 complexes form a ring around the inner region to form peripheral SMACs. A combination of central SMAC (signal 1) and peripheral SMAC (signal 2) is called the immunological synapse (Monks et al., 1998; Grakoui et al., 1999; Lee et al., 2002).

We discovered a novel and selective way to suppress autoimmune diseases (i.e., MS and type 1 diabetes) by using a bifunctional peptide inhibitor (BPI), which consists of an antigen peptide epitope and an ICAM-1-binding peptide conjugated via a spacer (Kobayashi et al., 2007, 2008; Murray et al., 2007). Although the mechanism of action of BPI is still unknown, we hypothesize that BPI molecules block the formation of the immunological synapse by simultaneously binding to the MHC-II and ICAM-1 on the APC to prevent the translocation and segregation of signal 1 and signal 2 during the formation of the immunological synapse (Kobayashi et al., 2007, 2008; Murray et al., 2007). In this case, the antigenic-peptide epitope 139-151 derived from the proteolipid protein (PLP139-151) was conjugated to LABL peptide derived from α6 integrin (CD11a327-246) to make BPI molecules (Kobayashi et al., 2007, 2008). To optimize the efficacy and lower the potential side effects of PLP-BPI molecules, the linker between the PLP and LABL peptides was modified, and the pharmacokinetic properties of the BPI molecule were evaluated. The effect of linker modification of BPI on the prophylactic and therapeutic activities was determined. The data of the pharmacokinetic profiles will be used to assess the safety profile of the BPI molecule and design future formulation and delivery methods for this type of molecule.

### Materials and Methods

#### Peptide Synthesis.
Peptides used in this study are listed in Table 1. The peptides were synthesized with 9-fluorenyl-methoxycarbonyl-protected amino acid chemistry on appropriate polyethylene glycol (PEG)-PS resin (GenScript Corporation, Piscataway, NJ) by using an automated peptide synthesizer (Pioneer; Applied Biosystems, Foster City, CA). Cleavage of the peptides from the resin and removal of the protecting groups from the side chain were carried out by using trifluoroacetic acid with scavengers. The crude peptides were purified by reversed-phase high-performance liquid chromatography using a preparatory C18 column with a gradient of solvent A [95%/5%, H2O (0.1% trifluoroacetic acid/acetonitrile) and solvent B (100% acetonitrile)]. The purity of the peptides was analyzed by high-performance liquid chromatography using an analytical C18 column.

### Mice.
SJL/J (H-2b) female mice were purchased from Charles River Laboratories, Inc. (Wilmington, MA) and housed under specific pathogen-free conditions at the Association for Assessment and Accreditation of Laboratory Animal Care-approved facility at the University of Kansas. All protocols involving live mice were approved by the university’s Institutional Animal Care and Use Committee.

#### Induction of EAE and Therapeutic Study.
Five- to 7-week-old SJL/J female mice were immunized subcutaneously with 200 µg of PLP139-151 in a 0.2 ml emulsion composed of equal volumes of phosphate-buffered saline (PBS) and complete Freund’s adjuvant (CFA) containing killed Mycobacterium tuberculosis strain H37RA (at a final concentration of 4 mg/ml; Difco, Detroit, MI). The PLP139-151/CFA was administered to regions above the shoulder and the flanks (total of four sites; 50 µl at each injection site). In addition, 200 ng of pertussis toxin (List Biological Laboratories Inc., Campbell, CA) was injected intraperitoneally on the day of immunization (day 0) and 2 days after immunization. The mice received intravenous injections of peptides (100 nmol/mouse) on the indicated days. For the therapeutic study, mice were left untreated until the day of disease onset.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>List of peptides used in the present study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Peptide</strong></td>
<td><strong>Sequence</strong></td>
</tr>
<tr>
<td>PLP139-151</td>
<td>HSLGKWLGHDPDFK</td>
</tr>
<tr>
<td>LABL (CD11a327-246)</td>
<td>ITDGEATDSG</td>
</tr>
<tr>
<td>Ac-PLP-BPI-NH2</td>
<td>Ac-HSLGKWLGHDPDF-K (Ac–Gac–Gac–Acp)–ITDGEATDSG-NH2</td>
</tr>
<tr>
<td>Ac-LABL-PLP-NH2</td>
<td>Ac-ITDGEATDSG-Acp-Gac-Gac-HSLGKWLGHDPDF-K</td>
</tr>
<tr>
<td>Ac-PLP-BPI-PEG3</td>
<td>Ac-HSLGKWLGHDPDFK-Acp(C2H5O)2Acp–ITDGEATDSG-NH2</td>
</tr>
<tr>
<td>Ac-PLP-BPI-PEG6</td>
<td>Ac-HSLGKWLGHDPDFK–(C2H5O)2–G–(C2H5O)2–ITDGEATDSG-NH2</td>
</tr>
<tr>
<td>Ac-PLP-BPI-PEG6ac</td>
<td>Ac-SLKHGGLWPHKDF–(C2H5O)2–G–(C2H5O)2–TDGITSGEADA-NH2</td>
</tr>
</tbody>
</table>
mained when the mouse had an experimental autoimmune encephalomyelitis (EAE) clinical score of one or more for the first time. Upon disease onset, the mice received intravenous injections of peptides (100 nmol/mouse) for 3 consecutive days of the maximum number of injections; peptide injection was discontinued once the disease score returned below one. Disease progression was evaluated by the same observer in a blinded fashion by using a clinical scoring as follows: 0, no clinical signs of the disease; 1, tail weakness or limp tail; 2, paraparesis (weakness or partial paralysis of one or two hind limbs); 3, paraplegia (complete paralysis of two hind limbs); 4, paraplegia with forelimb weakness or paralysis; and 5, moribund (mice were euthanized once they were found to be moribund). Body weight was also measured daily.

**Determination of IL-17 Levels in Serum In Vivo.** Blood samples were obtained from peptide-treated and untreated mice on days 12 and 35 (six mice per group). In addition, six unprimed and untreated mice (i.e., normal mice) were also sampled. Blood samples were allowed to clot overnight at 2 to 8°C before centrifuging for 20 min at 2000g. Serum was collected and stored at −20°C until analysis. Enzyme-linked immunosorbent assays (R&D Systems, Minneapolis, MN) for interleukin-17 (IL-17) in serum were performed according to the manufacturer’s instructions. Optical density was measured at 450 nm with correction at 540-nm wavelengths in a spectrophotometric microplate reader (TiterTek Multiskan MCC/340, Flow Industries, McLean, VA).

**Induction and Monitoring of Anaphylaxis.** Mice received subcutaneous immunization with PLP139-151/CFA on day 0 and intraperitoneal injection of pertussis toxin on the day of immunization and 2 days after immunization. Four to 5 weeks later, the mice were divided into groups and received intravenous injection of described peptides (100 nmol/mouse). To avoid the influence of the variation in their disease severity and history, all of the groups had a similar set of mice in terms of the average highest disease score, the average cumulative disease score, and the average day of disease onset. Incidence of anaphylactic response was judged by death occurring within 30 min or by the characteristic signs of immediate hypersensitivity, such as piloerection, prostration, erythema of the tail, ears, and footpads, shallow breathing, and lethargy, observed within a few minutes after peptide injection. Any mice that became moribund and did not recover from anaphylactic signs were euthanized.

**In Vivo Pharmacokinetic Studies in Rats.** Male Sprague-Dawley rats weighing 250 to 300 g were purchased from Charles River Laboratories, Inc. and housed under specific pathogen-free conditions at the Association for Assessment and Accreditation of Laboratory Animal Care-approved facility at the University of Kansas. All protocols involving live rats were approved by the university’s Institutional Animal Care and Use Committee. Before surgery, the animals were anesthetized with intraperitoneally administered ketamine (100 mg/kg) and xylazine (5 mg/kg). The right jugular vein was exposed and cannulated with medical-grade silastic tubing (0.020 inch, i.d. × 0.037 inch, o.d.). The vein was ligated with a 2-0 silk suture and anchored to the surrounding tissue with cyanoacrylate glue. The patency of the jugular catheter was maintained with sterile saline containing heparin (10 U/ml). The animal was maintained unconscious throughout the experiment by subcutaneously administered ketamine (25 mg/kg) and xylazine (5 mg/kg). The right jugular vein was exposed and cannulated with medical-grade silastic tubing (0.020 inch, i.d. × 0.037 inch, o.d.). The vein was ligated with a 2-0 silk suture and anchored to the surrounding tissue with cyanoacrylate glue. The patency of the jugular catheter was maintained with sterile saline containing heparin (10 U/ml). The animal was maintained unconscious throughout the experiment by subcutaneously administered ketamine (25 mg/kg). Baseline “blank” plasma was drawn from each animal immediately before dosing. An intravenous bolus dose was administered via the jugular vein over 30 s. After dosing, the jugular vein was flushed with sterile saline. Blood samples (~0.2 ml) were drawn from the jugular vein at scheduled time intervals for 10 h after dosing. The blood samples were immediately centrifuged at 10,000g for 3 min, and plasma was separated and stored at −70°C until analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS).

**Plasma Extraction Procedure.** To 95 μl of drug-free rat plasma, 5 μl of working solutions of Ac-PLP-BPI-NH2 and Ac-LABL-BPI-NH2 (internal standard, IS) was spiked to yield final concentrations in the range of 15 to 1000 pmol. Quality-control (QC) samples were prepared in a similar manner. All samples, QC’s, and standards were diluted with Nanopure water to 1 ml, vortexed for 30 s, and isolated from plasma by solid-phase extraction (Oasis HLB, Waters, Milford, MA). Solid-phase extraction cartridges were pretreated with 1 ml of methanol followed by 1 ml of water before the diluted samples were loaded. After running the samples through the cartridges, the cartridges were washed twice with 1.0 ml of 10% acetonitrile in water. Samples were eluted with 1.0 ml of 60% methanol with 2% trifluoroacetic acid in water, evaporated under nitrogen, and reconstituted with 100 μl of water/acetonitrile (1:1, v/v).

**LC-MS/MS Conditions.** The quantity of peptides recovered from plasma was determined by LC/MS/MS using a small, short C18 guard column and monitoring an abundant product ion from activation of a multiple-charged precursor of the peptide. Waters Acquity UPLC interfaced with a Micromass “triple” quadrupole mass spectrometer (Quattro Ultima Micromass Ltd., Manchester UK) was used. Samples were presented by using a Zorbax C18 (0.32 mm × 25 mm, 5 μm) column (Micro-Tech Scientific, Sunnyvale, CA) heated to 35°C and eluted with a mobile phase gradient at a flow rate of 60 μl/min. The injection volume was 10 μl. Mobile phase consisted of A (H2O with 1% CH3CN) and B (CH3CN with 0.08% formic acid). The gradient was 10% mobile phase B isocratic for 2 min, increased to 60% B in 1 min, then held at 60% B for 3 min. Multiple reaction monitoring mode was used for the quantification. The electrospray source block was 80°C, and the probe desolvation temperature was 200°C. Argon collision gas was set to attenuate the beam to 15% (8-4 mbar on a gauge near the collision cell). The cone voltage was 25 V. Quadropoles 1 and 3 were tuned to a resolution of 0.8 U full width at half-maximum. The selected transitions were from the M+H2 [585.1 > 724] collision energy 28 V for Ac-PLP-BPI-NH2-2 and mz 988.5 > 1069.8 collision energy 35V for Ac-LABL-BPI-NH2 (IS). Because of the high-charge state of the precursor, the optimum collision gas density and energy occur over a narrower range than commonly observed for singly charged ions.

**Pharmacokinetic Data Analysis.** Pharmacokinetic analysis of Ac-PLP-BPI-NH2-2 plasma concentration-time profiles after intravenous bolus injection was conducted by fitting the data to a two-compartment pharmacokinetic model using WinNonlin Professional Version 3.1 (Pharsight, Mountain View, CA) according to eq. 1:

\[
C = Ae^{-at} + Be^{-bt}
\]

Similarly, the initial volume of distribution (V0) was calculated according to eq. 2:

\[
V0 = \frac{D}{C_{max}}
\]

where C is the plasma concentration of Ac-PLP-BPI-NH2-2, A and B are pre-exponential constants, α is the distribution rate constant, β is the elimination rate constant, t is time, D is the dose, and Cmax is the maximum plasma concentration. The parameters that were calculated for Ac-PLP-BPI-NH2-2 included Cmax, area under curve (AUC)0→t, systemic clearance, and t1/2. Pharmacokinetic parameters were derived for each animal based on individual observed concentration-time data.

**Statistical Analysis.** Statistical comparisons among the groups in clinical disease scores were determined by calculating the average score for each mouse from the day of disease onset to the end of the study and performing a Mann-Whitney U test. Statistical differences among the groups in body weight were analyzed by calculating the average weight for each mouse for 10 days beginning on the day of disease onset and performing a Mann-Whitney U test. Statistical significance in EAE disease morbidity was determined by Cox proportional-hazards regression. Comparison of IL-17 concentration in serum was performed by one-way analysis of variance. All analyses were carried out with StatView (SAS Institute, Cary, NC).
Results

Effect of Linker Modification in BPI on the Suppression of EAE. The effects of the nature of the linker and its length were evaluated to optimize the in vivo efficacy of the BPI molecules. The hypothesis is that modification of linker properties will influence the efficacy and side effects of the BPI molecules. In this case, the Acp-G linker in Ac-PLP-BPI-NH₂-2 was modified with PEG with different lengths to give Ac-PLP-BPI-PEG3 and Ac-PLP-BPI-PEG6 (Table 1). The in vivo activities of Ac-PLP-BPI-PEG3, Ac-PLP-BPI-PEG6, and Ac-PLP-BPI-NH₂-2 were compared with PBS in therapeutic experiments using immunized SJL/J mice. In this case, the animals received intravenous injections of the peptides or PBS after they showed disease signs with a score of 1 or higher. The mice received intravenous injections of the peptides or PBS on consecutive days until the score was less than 1 or a maximum of three injections of the peptides, whichever came first. All three peptides reversed the disease signs with a score of 1 or higher. The PBS-treated mice recorded EAE clinical scores as high as 4, which included paralysis of their tails and limbs. To examine the necessity of the correct peptide sequence of the BPI molecule, an Ac-PLP-BPI-PEGSC peptide with scrambled sequences at both PLP and LABL fragments was used as a control. This peptide did not suppress the progression of EAE (Fig. 2A and B); suggesting that the correct sequences of both peptides is necessary for the activity to suppress EAE.

The therapeutic experiments were further corroborated by prophylactic experiments. In this case, the peptides were administered via intravenous route on days 4 and 7 before the onset of EAE. Ac-PLP-BPI-NH₂-2-treated mice showed clinical scores of mild EAE compared with the severe EAE found in PBS-treated mice, particularly at the peak of the disease on days 12 to 17 ($p < 0.001$) (Fig. 2A). Ac-PLP-BPI-NH₂-2 treated mice had significant ($p < 0.001$) minimal loss of body weight compared with the control as shown in Fig. 2B. At the peak of disease severity (days 12–17), PBS-treated mice had as much as 24% loss in body weight compared with a maximum 11% loss in body weight among the Ac-PLP-BPI-NH₂-2-treated mice (Fig. 2B). Similarly, intravenous injections of Ac-PLP-BPI-PEG6 inhibited the progression and severity of EAE similar to that of Ac-PLP-BPI-NH₂-2 ($p > 0.05$). The PBS-treated mice recorded EAE clinical scores as high as 4, which included paralysis of their tails and limbs. To examine the necessity of the correct peptide sequence of the BPI molecule, an Ac-PLP-BPI-PEGSC peptide with scrambled sequences at both PLP and LABL fragments was used as a control. This peptide did not suppress the progress of EAE (Fig. 2A and B); suggesting that the correct sequences of both peptides is necessary for the activity to suppress EAE.

The effect of linker modification on reducing the anaphylaxis side effect of the peptides was evaluated by multiple injections of the peptides on the treated animals during the late phase of the disease (i.e., 35 days) (Table 2). The animals treated with Ac-PLP-BPI-PEG6 have lower anaphylactic response (22%; Table 2) compared with those treated with the Ac-PLP-BPI-NH₂-2 (45%). As found previously, the animals treated with PLP₁₃₉₋₁₅₁ had the highest anaphylactic response (87%). This suggests that BPI molecules have lower side effects than the plain PLP₁₃₉₋₁₅₁; in addition, changing the linker from Acp-G repeat to PEG repeat lowers the side effects of the BPI molecules. As a control, the scrambled peptide (i.e., Ac-PLP-BPI-PEG6SC) did not induce any ana-
phylactic reaction (0%). Studies by Kuchroo et al., 1994 identified specific residues in the antigenic core that are TCR binding sites and MHC-II binding sites. Their findings indicated that residues Trp-144 and His-147 were the TCR binding sites, whereas residues Leu-145 and Pro-148 were important for MHC-II binding. Thus, any changes in the position of these amino acids will affect the MHC-II and TCR binding properties as well as peptide activity. Because the sequence in Ac-PLP-BPI-PEGSC is scrambled, it is expected that Ac-PLP-BPI-PEGSC has no suppressive activity and anaphylactic reaction in the EAE mouse model.

IL-17 Serum Levels in SJL/J Mice In Vivo. The effect of linker modification of BPI molecules on suppressing the IL-17 levels was evaluated because IL-17 is a marker for the progress of MS. In this study, the animals were treated with Ac-PLP-BPI-NH2-2, Ac-PLP-BPI-PEG6, or PBS on days 4, 7, and 10, and IL-17 levels were measured on days 12 and 35 (Fig. 3A). As expected, the clinical scores, body weight changes, and disease incidence (Fig. 3) indicated that both peptides have better efficacy than PBS. Three injections of the peptides provided lower disease incidence (Fig. 3D) than did two injections on days 4 and 7 (Fig. 2C). In the mice treated with Ac-PLP-BPI-NH2-2 or Ac-PLP-BPI-PEG6, the amount of IL-17 was significantly decreased from days 12 to 35; in contrast, the mice treated with PBS had higher levels of IL-17 on day 35 than on day 12. However, on day 12, mice receiving Ac-PLP-BPI-NH2-2 or Ac-PLP-BPI-PEG6 had unexpectedly significantly high serum levels of IL-17 compared with the mice receiving PBS alone ($p < 0.001$) (Fig. 3A). At the end of the study (day 35), mice receiving Ac-PLP-BPI-NH2-2 or Ac-PLP-BPI-PEG6, the amount of IL-17 was significantly decreased from days 12 to 35; in contrast, the mice treated with PBS had higher levels of IL-17 on day 35 than on day 12. However, on day 12, mice receiving Ac-PLP-BPI-NH2-2 or Ac-PLP-BPI-PEG6 had unexpectedly significantly high serum levels of IL-17 compared with the mice receiving PBS alone ($p < 0.001$) (Fig. 3A). At the end of the study (day 35), mice receiving Ac-PLP-BPI-NH2-2 or Ac-PLP-BPI-PEG6 had significantly lower IL-17 serum concentration ($p < 0.01$) than did PBS-treated mice. Although there was a trend that the level of IL-17 was lower in the Ac-PLP-BPI-PEG6-treated group than in the Ac-PLP-BPI-NH2-2-treated group on day 35, there was no significant difference ($p > 0.05$) between these levels of IL-17. Measured serum levels of IL-17 in the unprimed mice were found to be $2.77 \pm 4.48$ pg/ml (Fig. 3D), representing the background level of IL-17 in mouse. As anticipated, these levels were the lowest IL-17 serum concentration among all of the groups.

**Pharmacokinetic Analysis of Ac-PLP-BPI-NH2-2 in Sprague-Dawley Rats.** For pharmacokinetic studies, plasma concentrations of Ac-PLP-BPI-NH2-2 were determined by LC-MS/MS. We chose Ac-PLP-BPI-NH2-2 as our model BPI compound to study pharmacokinetics because we had done extensive studies on this compound in terms of its efficacy, potential to cause hypersensitivity, and cytokine profiling after treatment in our previous experiments. The initial step in analysis of extracted plasma samples involved the development and validation of the LC-MS/MS analytical method. It was found that a gradient mobile phase composition pro-

**Table 2**

<table>
<thead>
<tr>
<th>Treatment on Days 4 and 7</th>
<th>Peptide Challenge on Day 35</th>
<th>Incidence of Anaphylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>PLP139-151</td>
<td>13/15 (87%)</td>
</tr>
<tr>
<td>Ac-PLP-BPI-NH2-2</td>
<td>Ac-PLP-BPI-NH2-2</td>
<td>9/20 (45%)</td>
</tr>
<tr>
<td>Ac-PLP-BPI-PEG6</td>
<td>Ac-PLP-BPI-PEG6</td>
<td>4/18 (22%)</td>
</tr>
<tr>
<td>Ac-PLP-BPI-PEG6sc</td>
<td>Ac-PLP-BPI-PEG6sc</td>
<td>0/19 (0%)</td>
</tr>
</tbody>
</table>

**Fig. 2.** In vivo EAE-suppressive activity of BPI derivatives in the mouse EAE model. PLP139-151/CFA-immunized mice received intravenous injections of the indicated peptide (100 nmol/mouse/day) on days 4 and 7. A, clinical EAE disease score. B, change in body weight. C, incidence of disease. Results are expressed as the mean ± S.D. ($n = 10$). There are significant differences between BPI-treated and PBS-treated groups in clinical EAE disease scores and loss of body weight: Ac-PLP-BPI-NH2-2, $p < 0.001$ and Ac-PLP-BPI-PEG6, $p < 0.001$. There was no significant difference ($p > 0.05$) in EAE clinical scores and loss of body weight between scrambled peptide (Ac-PLP-BPI-PEG6sc) and PBS groups. In addition, no significant difference ($p > 0.05$) between Ac-PLP-BPI-NH2-2 and Ac-PLP-BPI-PEG6 was observed.
vided good resolution, symmetric peak shapes of analytes, and short run time. The retention times were 2.44 and 3.48 min for Ac-PLP-BPI-NH$_2$-2 and IS, respectively. No significant interfering peaks caused by endogenous compounds were observed at the retention times of the two analytes of interest. The standard calibration curves of Ac-PLP-BPI-NH$_2$-2 in plasma were linear over the concentration range of 15 to 1000 pmol. Typical mean ($n$ = 3) calibration curves were $y = 0.0066x - 0.6754$, $R^2 = 0.999$, where $y$ and $x$ are the peak area ratio of analyte to IS and concentration, respectively. The mean plasma extraction recoveries for Ac-PLP-BPI-NH$_2$-2 and Ac-LABL-BPI-NH$_2$ (IS) determined in triplicate in the concentration range of 15 to 1000 pmol were 91.8% (%CV 5.8) and 98.4% (%CV 4.3), respectively. The peak areas of the analytes in the reconstituted QC samples had a CV of less than 10%, indicating that the extracts were “clean” with no coeluting compounds that could influence ionization of the analyte or the IS. The lower limit of quantification defined as the concentration of Ac-PLP-BPI-NH$_2$-2 that can still be determined with acceptable precision (%CV <10) and accuracy (www.fda.gov/cvm) was found to be 75 pmol, and the limit of detection was 35 pmol. Results of the intraday and interday validation assays indicated that the accuracy of the assay was >90% with a CV that did not exceed 10%. For at least 48 h at the autosampler temperature (12°C), no significant degradation was observed in the extracted and reconstituted plasma samples or in working solutions. Ac-PLP-BPI-NH$_2$-2 and the IS in the final extract were considered to be stable when 85 to 115% of the initial concentration was found.

The validated LC-MS/MS method was applied to a pharmacokinetic study of Ac-PLP-BPI-NH$_2$-2 after administration of intravenous injections in Sprague-Dawley rats. Mean plasma concentration-time profiles of Ac-PLP-BPI-NH$_2$-2 after injections of 0.3, 0.9, 1.8, and 5.0 μmol/kg i.v. are shown in Fig. 4, and the related pharmacokinetic parameters are listed in Table 3. Observed plasma concentration-time profile followed a two-compartmental model characterized by a rapid distribution phase and a gradual elimination phase and had a good correlation ($R^2 = 0.9872$) with the predicted plasma concentration. Ac-PLP-BPI-NH$_2$-2 $C_{max}$ of 3.64 ± 1.03, 18.17 ± 4.50, 69.59 ± 19.69, and 116.05 ± 24.92 nmol/ml were observed at doses of 0.3, 0.9, 1.8, and 5.0 μmol/kg, respectively.

Discussion

In our recent studies, it was found that in vivo activity of PLP-BPI could be improved further by increasing its plasma stability and optimizing the separation distance between PLP and LABL peptides. Because the original PLP-BPI has uncapped N and C termini, it may be susceptible to aminopeptidase and carboxyl-peptidase degradation in the blood. The rate of degradation can be decreased tremendously or halted by capping the N and C termini by acetylation and amidation, respectively.

![Fig. 3. Production of IL-17 in serum in vivo. SJL/J female mice were immunized subcutaneously with PLP$_{139-151}$/CFA and injected intraperitoneally with pertussis toxin on days 0 and 2. Then, the mice received intravenous injections of the indicated peptide (100 nmol/mouse/day) or PBS on days 4, 7, and 10. A, serum concentration of IL-17 determined on days 12 and 35 in Ac-PLP-BPI-NH$_2$-2-treated, Ac-PLP-BPI-PEG6-treated, PBS-treated, and unprimed mice by using enzyme-linked immunosorbent assays. Data are represented as mean ± S.D. (six mice per group), and experiments were done in duplicate. B to D, disease progression was evaluated by EAE clinical disease score (B), percentage change in body weight (C), and incidence of disease (D). There are significant differences between BPI-treated and PBS-treated groups in clinical disease scores and loss of weight: Ac-PLP-BPI-NH$_2$-2, $p < 0.001$ and Ac-PLP-BPI-PEG6, $p < 0.001$. There was no significant difference ($p > 0.05$) in EAE clinical scores and loss of body weight between Ac-PLP-BPI-NH$_2$-2 and Ac-PLP-BPI-PEG6.
respectively. In our observations, a single injection of Ac-PLP-BPI-NH₂ with capped N and C termini inhibited the onset and progression of EAE more efficiently than uncapped PLP-BPI (Kobayashi et al., 2008), and there was no significant difference between Ac-PLP-BPI-NH₂ and PLP-BPI upon four injections of the two different peptides. It is plausible that the improved efficacy of Ac-PLP-BPI-NH₂ is caused by increased bioavailability and lower metabolic degradation compared with the parent PLP-BPI. Ac-PLP-BPI-NH₂ was further optimized by doubling the linker length to give Ac-PLP-BPI-NH₂-2. In vivo studies in SJL/J mice revealed that Ac-PLP-BPI-NH₂-2 has activity similar to that of Ac-PLP-BPI-NH₂ but lower anaphylaxis reaction, suggesting that the linker properties and length may have a role in the hypersensitivity reaction of the BPI molecules.

The therapeutic effectiveness and the presence of potential side effects of our BPI molecules could also be caused by their pharmacokinetic properties. Therefore, to move closer to clinical use of these peptides, we need to evaluate their pharmacokinetic profiles. For practical reasons such as the need for frequent sampling and sampling volume, male Spraque-Dawley rats were used instead of mice. In the present study, we conducted pharmacokinetic studies of Ac-PLP-BPI-NH₂-2 after intravenous administration. Mean plasma concentration-time profiles of Ac-PLP-BPI-NH₂-2 after injections of 0.3, 0.9, 1.8, and 5.0 μmol/kg i.v. are shown in Fig. 4, and the related pharmacokinetic parameters are listed in Table 3. Although there was no proportionality, there was an increase in the C_{max} with an increase in the dose administered. This trend was also observed in the AUC values, suggesting that systemic exposure (C_{max} and AUC) of Ac-PLP-BPI-NH₂-2 increased with an increase in dose administered. Except for the smaller clearance values at the dose of 0.3 μmol/kg, there were no significant differences (p > 0.05) in the clearance values and t_{1/2} at doses of 0.3, 0.9, 1.8, and 5.0 μmol/kg. This fairly dose-independent disposition (systemic clearance and t_{1/2}) of Ac-PLP-BPI-NH₂-2 suggests nonsaturable hepatic extraction. As with any peptide, Ac-PLP-BPI-NH₂-2 is expected to have extensive hepatic extraction and, in the case of saturable hepatic extraction, we anticipate that the clearance values should increase with a decrease in the dose administered. On the other hand, elimination t_{1/2} is expected to decrease with a decrease in the dose administered. However, the observed pharmacokinetics was inconclusive because of the limited dose range investigated. The results from this study indicate that the BPI molecules are cleared rapidly upon intravenous administration; thus, an alternative route of administration such as subcutaneous injection may be more favorable. Recently, subcutaneous injection of BPI molecules has been shown to be more than or as effective as intravenous injection; thus, the subcutaneous route will be more desirable for delivering the BPI molecules. Pharmacokinetic studies of BPI molecules upon subcutaneous injection with various formulations, including nanoparticle delivery methods, are being investigated.

This study shows that modification of the linker can affect in vivo properties of the BPI molecules, especially in reducing side effects. Modification of Acp-G-linker in Ac-PLP-BPI-NH₂-2 to a more hydrophilic PEG6-linker with a similar length in Ac-PLP-BPI-PEG6 lowers the hypersensitivity reaction of the peptides. It was previously shown that PLP-BPI molecules have lower hypersensitivity reactions than PLP₁₃₉₋₁₅₁ peptide, which has the highest hypersensitivity reactions in this study (Table 2). Ac-PLP-BPI-NH₂-2 and Ac-PLP-BPI-PEG6 have similar in vivo activities in suppressing EAE in the animal model, whereas Ac-PLP-BPI-PEG3 with a shorter linker has lower activity, indicating that the distance separation between the two peptides is important for peptide in vivo activity.

Although short linear peptides generally lack the ability to cross-link adjacent IgE molecules on mast cells and basophils (Alexander et al., 2002), repeated injections of peptides have been shown to induce hypersensitivity in MS patients (Smith

### Table 3
Summary of pharmacokinetic parameters of Ac-PLP-BPI-NH₂-2 after intravenous administration

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Units</th>
<th>5 μmol/kg</th>
<th>1.8 μmol/kg</th>
<th>0.9 μmol/kg</th>
<th>0.3 μmol/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC</td>
<td>nmol × h/ml</td>
<td>41.35 ± 3.20</td>
<td>22.73 ± 1.84</td>
<td>9.97 ± 2.88</td>
<td>6.55 ± 0.24</td>
</tr>
<tr>
<td>C_{max}</td>
<td>nmol/ml</td>
<td>116.05 ± 24.92</td>
<td>69.59 ± 19.69</td>
<td>18.17 ± 4.50</td>
<td>3.84 ± 1.93</td>
</tr>
<tr>
<td>α</td>
<td>h⁻¹</td>
<td>7.06 ± 1.70</td>
<td>7.88 ± 2.23</td>
<td>10.17 ± 2.46</td>
<td>4.69 ± 2.83</td>
</tr>
<tr>
<td>β</td>
<td>h⁻¹</td>
<td>0.36 ± 0.15</td>
<td>0.26 ± 0.19</td>
<td>0.29 ± 0.06</td>
<td>0.23 ± 0.07</td>
</tr>
<tr>
<td>A</td>
<td>nmol/ml</td>
<td>106.71 ± 25.82</td>
<td>65.85 ± 19.69</td>
<td>15.99 ± 3.71</td>
<td>2.51 ± 0.95</td>
</tr>
<tr>
<td>B</td>
<td>nmol/ml</td>
<td>9.34 ± 4.24</td>
<td>3.74 ± 2.62</td>
<td>2.18 ± 0.81</td>
<td>1.34 ± 0.49</td>
</tr>
<tr>
<td>Systemic clearance</td>
<td>liter/h/kg</td>
<td>0.12 ± 0.04</td>
<td>0.08 ± 0.01</td>
<td>0.01 ± 0.03</td>
<td>0.05 ± 0.00</td>
</tr>
<tr>
<td>V_d</td>
<td>liter/kg</td>
<td>0.24 ± 0.07</td>
<td>0.25 ± 0.12</td>
<td>0.32 ± 0.11</td>
<td>0.20 ± 0.05</td>
</tr>
<tr>
<td>V_{initial}</td>
<td>liter/kg</td>
<td>0.04 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.05 ± 0.01</td>
<td>0.08 ± 0.03</td>
</tr>
<tr>
<td>t_{1/2}</td>
<td>h</td>
<td>2.17 ± 0.86</td>
<td>3.55 ± 2.06</td>
<td>2.73 ± 0.63</td>
<td>3.28 ± 0.91</td>
</tr>
</tbody>
</table>
et al., 2005). Clinical implications of anaphylaxis are illustrated by the termination of a phase II clinical trial using an altered peptide ligand (APL) derived from myelin basic protein 85–99 to regulate MS because of the patients developed systemic hypersensitivity (Bielekova et al., 2000; Kappos et al., 2000). It has been suggested that the peptide induces the production of anti-IgG1 and anti-IgE antibodies. The administration of anti-IgE antibodies can block myelin peptide-induced anaphylaxis, suggesting that the hypersensitivity reaction is via an IgE-dependent mechanism (Smith et al., 2005). The anaphylaxis reaction in an animal model can be avoided by formation of an APL of myelin oligodendrocyte protein (MOG)35–55 peptide with mutation of the Ala residue at position 37 to Ala to produce MOG-Ala37. The MOG-Ala37 mutant does not bind to IgG1 from the serum of mice immunized with MOG35–55/CFA; this peptide suppressed EAE and, upon repeated injection, did not generate anaphylaxis reaction (Leech et al., 2007). Thus, this method is useful for designing BPI molecules that have no hypersensitivity reaction. In this study, the difference in hypersensitivity among mice receiving lower doses of BPI molecules (≤100 nmol/injection) reduces hypersensitivity reactions, suggesting that induction of anaphylaxis by BPI molecules is dose-dependent. A similar observation was found in a clinical trial of APL in which lower doses of peptide administration were shown to reduce side effects of the peptide administration. Therefore, the effect of dose of BPI molecules on the sensitivity reaction is currently being investigated to find the optimal dose that is both low and well tolerated.

The possible mechanisms of action of BPI molecules are elucidated by measuring their effect on IL-17 production as a result of injection of soluble peptide. It is now known that TGF-β and IL-6 play an important role in the induction of Th17 differentiation (Korn et al., 2009; Morishima et al., 2009). Interestingly, there was a significant decrease in IL-17 production among PBS-treated mice on day 35, suggesting the possibility of an increased and/or an impending relapse of EAE. A better understanding of the up-regulation/down-regulation of IL-17 would be gained through studies carried out for periods much longer than 35 days and using priming agents other than PLP139-151.

As mentioned previously, the central hypothesis is that the BPI molecules simultaneously bind to MHC-II and ICAM-1 of the immunological synapse at the surface of APCs and selectively alter or suppress the activation of a subpopulation of autoreactive T cells in an antigen-specific manner. Thus, we anticipate that BPI should modulate only those immune responses involved in EAE while minimizing the nonspecific suppression of the entire immune system. Another BPI molecule called GAD-BPI had been shown to colocalize the MHC-II and ICAM-1 on the surface of APCs (B cells) isolated from nonobese diabetic mice (Murray et al., 2007). However, how this colocalization event regulates and alters the commitment of T cells has not been fully elucidated. The mechanisms of action of BPI molecules could also be explained by invoking the mechanism of peptide vaccines as antigen-specific immunotherapy (Fig. 5). When dendritic cells encounter insoluble antigen or complex molecules found on microbes such as bacteria and viruses, they are up-regulated and mature, presenting the processed antigenic peptides using
MHC-II molecules on their surface. As they mature, they up-regulate the costimulatory molecules required for full activation of T cells, thus leading to allergic and autoimmunity response upon recognition of the antigenic peptides by the TCRs. This paradigm is based on findings that insoluble peptides can induce local inflammation (Shen et al., 2003), whereas soluble peptides can bind directly to dendritic cells in lymphoid tissues (Santambrogio et al., 1999; Metzler et al., 2000) and may activate regulatory T cells (Tregs) (Dhodapkar et al., 2001; Menges et al., 2002). It has been suggested that the soluble peptide vaccine binds mostly to steady-state (immature) APCs such as dendritic cells. Likewise BPI molecules bind to steady-state APCs, and upon binding of these loaded APCs to naive T cells, the T cells differentiate into Tregs, which produce IL-10 (Larche and Wraith, 2005). The IL-10-producing T-regs, which produce IL-10 (Larche and Wraith, 2005). The IL-10-producing T-regs are in part responsible for the EAE-suppressive activity of BPI (Kobayashi et al., 2007, 2008). However, this does not satisfactorily explain why BPI was much more effective than PLP in suppressing EAE (Kobayashi et al., 2007) or why there were differences in activities of various BPI derivatives. Thus, it is also possible that the BPI molecule binds to mature dendritic cells via simultaneous binding to MHC-II and ICAM-1, which prevents the formation of the immunological synapse formation upon binding of mature dendritic cells to T cells (Fig. 5). This inhibition of the immunological synapse formation generates IL-4-producing Th2 cells as previously observed (Kobayashi et al., 2007). Thus, the BPI molecule acts via two different routes to suppress the T-cell activation whereas PLP peptide alone acts via Treg activation by binding to immature dendritic cells. These possible mechanisms currently are being investigated in more detail.

In conclusion, Ac-PLP-BPI-PEG6 effectively inhibited the onset, severity, and incidence of EAE, and its EAE-suppressive activity was comparable with that of Ac-PLP-BPI-NH2-2. The Ac-PLP-BPI-PEG6 treatment has also been shown to lower hypersensitivity reactions compared with Ac-PLP-BPI-NH2-2 and PLP treatment of EAE animals. Further alteration of the structure of BPI molecules may eliminate the hypersensitivity reaction. Currently, the mechanisms of action of BPI molecules and their dosing methods are also being investigated for efficacy optimization and lowering of their side effects. Finally, altering the structure and sequence of BPI molecules will lead to a more efficient and safer BPI-based therapy for MS.

Acknowledgments

We thank Nancy Harmony for proofreading this manuscript.

References


Address correspondence to: Dr. Teruna J. Siahaan, Department of Pharmaceutical Chemistry, University of Kansas, Simons Research Laboratories, 2095 Constant Avenue, Lawrence, KS 66047. E-mail: siahaan@ku.edu.